Ambien Nightmare? Sanofi Marketing Targeted In Civil Class Action
This article was originally published in The Pink Sheet Daily
Executive Summary
A class action suit alleges Sanofi-Aventis failed to adequately warn patients of the risk of sleep walking and sleep eating associated with the insomnia product.
You may also be interested in...
Sedative Hypnotic Class Labeling Warns Of Sleep-Driving And “Complex” Behaviors
FDA requests manufacturers of 13 sleep aids, including Ambien, Lunesta and Rozerem, to update labeling to advise of adverse events.
Sedative Hypnotic Class Labeling Warns Of Sleep-Driving And “Complex” Behaviors
FDA requests manufacturers of 13 sleep aids, including Ambien, Lunesta and Rozerem, to update labeling to advise of adverse events.
Ambien Publicity Sets The Whole Class On Snooze, Sanofi Says
Despite an initial dip in sales during Q1 stemming from a class action suit, Sanofi-Aventis says growth of the insomnia drug returned to previous levels.